Shoji Kubo, MD; Shuhei Nishiguchi, MD; Kazuhiro Hirohashi, MD; Hiromu Tanaka, MD; Taichi Shuto, MD; Osamu Yamazaki, MD; Susumu Shiomi, MD; Akihiro Tamori, MD; Hiroko Oka, MD; Sumito Igawa, MD; Tetsuo Kuroki, MD; Hiroaki Kinoshita, MD
Interferon therapy decreases the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
To evaluate effects of interferon-Î± on recurrence after resection of hepatitis C virusâ€“related hepatocellular carcinoma.
Randomized, controlled trial.
University hospital, medical center, and affiliated hospital in Osaka, Japan.
30 men were randomly allocated after resection to the interferon-Î± group (n = 15) or the control group (n = 15).
Patients in the interferon-Î± group received interferon-Î±, 6 MIU intramuscularly daily for 2 weeks, then three times weekly for 14 weeks, and finally twice weekly for 88 weeks.
Recurrence rates after resection.
Recurrent tumors were detected in 5 patients in the interferon-Î± group and in 12 control patients. The recurrence rate was significantly lower in the interferon-Î± group than in the control group (PÂ =Â 0.037).
Postoperative interferon-Î± therapy appears to decrease recurrence after resection of hepatitis C virusâ€“related hepatocellular carcinoma.
Learn more about subscription options.
Register Now for a free account.
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of Long-Term Postoperative Interferon-α Therapy on Intrahepatic Recurrence after Resection of Hepatitis C Virus–Related Hepatocellular Carcinoma: A Randomized, Controlled Trial. Ann Intern Med. 2001;134:963-967. doi: 10.7326/0003-4819-134-10-200105150-00010
Download citation file:
Published: Ann Intern Med. 2001;134(10):963-967.
Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology, Infectious Disease, Liver Cancer.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only